Drug intelligence / Profile preview

Zhengqi Pian

Development stage: Unknown
Lead developer: Shanghai Hutchison Pharmaceuticals
Administration: Oral

Overview

Zhengqi Pian (正气片) is a traditional Chinese medicine (TCM) oral tablet developed and manufactured by Shanghai Hutchison Pharmaceuticals. It is an approved TCM herbal formulation primarily indicated for the treatment of "gastrointestinal cold" (胃肠型感冒), a condition characterized by digestive upset and respiratory symptoms. The drug has also been investigated for its potential in COVID-19 prevention research. As a complex TCM preparation, its mechanism of action is based on traditional principles of balancing "qi" and resolving dampness, rather than targeting specific molecular pathways. It has expanded its regulatory footprint internationally, obtaining a Natural Health Product license in Canada.

Brand names: Zhengqi Pian
Other names: 正气片Zhengqi Tablets

Beyond the preview

Go deeper on Zhengqi Pian.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhengqi Pian.

Explore the full profile